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Abstract 
Background: Glioblastoma is an aggressive malignant brain tumor with exceptionally poor prognosis. 
Currently, patients with this diagnosis receive a combination of chemotherapy, surgical debulking, as well 
as radiation therapy. Recently, a new device has been FDA approved for treatment of glioblastoma called 
the NovoTTF-100A system. Research has shown improvement of patients’ lives as well as prolonged 
survival. The focus of this systematic review is to evaluate if the NovoTTF-100A system could be an 
effective addition to the standard of care for patients with glioblastoma. 
Methods: An exhaustive medical literature search was completed using MEDLINE-Ovid, Web of Science, 
and Google Scholar. The keyword used was Novo-TTF100A system. The quality of the selected articles 
were assessed using the Grading of Recommendations, Assessment, Development, and Evaluation 
(GRADE) system. 
Results: Of the 83 articles screened in the initial search, only 2 met the criteria for review. Both of the 
selected studies showed prolonged median overall survival for patients treated with NovoTTF-100A 
therapy, whether that be alone or in combination with other front line treatments. One study was low 
quality, and the other was very low quality when using the GRADE system. 
Conclusion: The NovoTTF-100A system is associated with positive outcomes in the treatment of 
glioblastoma. No significant adverse events were recorded with the use of this therapy, only some 
localized skin irritation. The NovoTTF-100A therapy does seem to be beneficial to patients with 
glioblastoma, but further research needs to be done to find out which patients would and would not 
benefit as much from the therapy. 
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Abstract   
 
Background: Glioblastoma is an aggressive malignant brain tumor 
with exceptionally poor prognosis. Currently, patients with this 
diagnosis receive a combination of chemotherapy, surgical debulking, 
as well as radiation therapy. Recently, a new device has been FDA 
approved for treatment of glioblastoma called the NovoTTF-100A 
system. Research has shown improvement of patients’ lives as well as 
prolonged survival. The focus of this systematic review is to evaluate if 
the NovoTTF-100A system could be an effective addition to the 
standard of care for patients with glioblastoma. 
 
Methods:  An exhaustive medical literature search was completed 
using MEDLINE-Ovid, Web of Science, and Google Scholar. The 
keyword used was Novo-TTF100A system. The quality of the selected 
articles were assessed using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) system. 
 
Results:  Of the 83 articles screened in the initial search, only 2 met 
the criteria for review. Both of the selected studies showed prolonged 
median overall survival for patients treated with NovoTTF-100A 
therapy, whether that be alone or in combination with other front line 
treatments. One study was low quality, and the other was very low 
quality when using the GRADE system. 
 
Conclusion:  The NovoTTF-100A system is associated with positive 
outcomes in the treatment of glioblastoma. No significant adverse 
events were recorded with the use of this therapy, only some localized 
skin irritation. The NovoTTF-100A therapy does seem to be beneficial 
to patients with glioblastoma, but further research needs to be done to 
find out which patients would and would not benefit as much from the 
therapy. 
 
Keywords:  NovoTTF-100A, Glioblastoma  
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NovoTTF-100A System as a treatment for 
Glioblastoma  
BACKGROUND 
Glioblastoma is an aggressive neurological cancer from which 
most patients do not survive longer than 1-2 years.1 The current 
treatment protocol consists of a combination of chemotherapy, surgery 
for tumor resection, and radiation therapy. The treatment protocol is 
based on the tumor location as well as the patient’s prognosis and 
severity at diagnosis.  
The NovoTTF-100A system is a new type of therapy that has 
recently been FDA approved for treatment of supratentorial 
glioblastoma.2 It is a helmet device that sends tumor treatment fields 
(TTF) in alternating intensities of radiofrequency waves through the 
brain that physically interrupt cell synthesis and division.2,3 For the 
device to work effectively in tumor suppression, it is important for 
patients to wear it continuously, for a minimum of 4 weeks.3 It is 
suggested that patients wear the device for 18+ hours a day during 
each 4-week treatment period.3 This new treatment method has not 
been added to the standard of care for patients at this time.  
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This review will address if the NovoTTF-100A system could be an 
effective addition to the standard of care for patients with 
glioblastoma. If the NovoTTF-100A system proves to be an effective 
method of treatment in patients with glioblastoma, it would be 
beneficial to have it added to the routine standard of care for patients 
to have access to it as a primary treatment option. 
METHODS 
An exhaustive medical literature search was completed in June 
of 2017 using MEDLINE-Ovid, Web of Science, and Google Scholar. 
The key word included in the search was NovoTTF-100A system. 
Studies reviewed were narrowed to include studies that enrolled 
patients with glioblastoma, done within the last 10 years, published in 
the English language, and conducted on humans. Studies that included 
treatment of cancers other than glioblastoma were excluded. Selected 
articles were assessed using the GRADE (Grading of 
Recommendations, Assessment, Development, and Evaluation) system 
for overall quality.4  
 
RESULTS 
The medical literature search lead to the review of 83 articles. All 
articles were screened for inclusion criteria (15 articles were screened 
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using OVID, 22 articles in Web of Science, and 46 articles in Google 
Scholar), and 2 articles1,3 were selected to meet the stated criteria. 
One study1 is a randomized control trial, that examined the difference 
between combination chemotherapy and the Novo-TTF100A System, 
to chemotherapy alone.
 
The second study3 is an observational cohort 
study, that compiled data from a Patient Registry Dataset (PRiDe) of 
all glioblastoma (GBM) patients who received Novo-TTF as therapy. 
See Table 1. 
Stupp et al 
 This randomized control trial1 examined 695 patients, 
randomizing them in a 2:1 fashion to receive the chemotherapy 
temozolomide alone or in combination with the NovoTTF-100A 
therapy. There were 466 patients who received combination therapy, 
while 229 patients received temozolomide alone. The patients 
receiving NovoTTF-100A therapy wore the device for >18 hours per 
day for a total of 5 days in a 28-day cycle. This trial was evaluated 
with interim analysis, as the trial was terminated due to the 
overwhelmingly positive results. In the interim analysis, 210 patients 
were given combination therapy and 105 received temozolomide 
alone. The interim analysis was completed with these patients after 
they finished more than 18 months of follow up. The patients were all 
evaluated using the intent-to-treat (ITT) model.1   
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The study measured progression-free survival as the primary 
endpoint in the ITT analyzed population. The secondary endpoint 
measured was overall survival, in the per-protocol population of 280 
patients. Of the 315 patients in the interim analysis, 75% (n=157) 
were compliant with therapy (average of >18 hours per day for the 
first 3 months). Median follow up was completed after 38 months, and 
in the NovoTTF plus temozolomide therapy group median progression-
free survival was calculated at 7.1 months (95% CI, 5.9-8.2 months). 
In the control group with temozolomide alone, the median 
progression-free survival was calculated as 4.0 months (95% CI, 3.3-
5.3 months). The hazard ratio calculated for this difference is 0.64 
(99.4% CI 0.42-0.98). The ITT population treated with Novo TTF was 
also shown to have a longer median overall survival of 19.6 months 
(95% CI, 16.6-24.4 months), when compared to the chemotherapy 
alone group of 16.6 months (95% CI, 13.6-19.2 months).1 These 
results along with those of the per protocol population can be found 
summarized in Table 2. 
There were no increase in major adverse events recorded during 
the study with the addition of the NovoTTF to the standard 
chemotherapy protocol. The main adverse event found was localized 
skin reactions due to the application of the NovoTFF device directly on 
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the scalp. Some seizures were reported, but the outcomes were well 
balanced between the two groups.1 
Mrugala et al 
 This observational cohort study3 evaluated 457 patients with 
GBM in various cancer centers across the US that were using the 
NovoTTF-100A therapy. All patients that were 18 years or older that 
used NovoTTF-100A for treatment of recurrent GBM between October 
2011 and November 2013 were considered for the data analysis. The 
patients were not restricted to conjunctive or prior therapies used in 
addition to NovoTTF-100A. Prognostic variables that were measured 
were median overall survival (OS), recurrences, age, KPS (Karnofsky 
Performance Status which measure functional impairment), 
bevacizumab use, surgeries, as well as adverse events. In addition to 
the various prognostic variables, compliance was also monitored on a 
monthly basis according to the daily time Novo-TTF delivered fields.3 
 Data was analyzed using survival curves in comparison with 
treatment duration. Median OS was 9.6 months with Novo-TTF 
therapy, when the best chemotherapy group showed a median OS of 
6.0 months. One- and 2-year OS in patients using Novo-TTF therapy 
were more than double when compared to the best chemotherapy.3 
The data is summarized in FIGURE 1. 
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 Compliance data began to be collected in January 2013, so it 
was not available for all 457 patients in the study. It was able to be 
collected for 63% of the patients (287), and the calculated median 
daily compliance was 70%. It was found that those who had daily 
compliance >75% had markedly longer median OS as well (HR 0.43).3  
Throughout the duration of the study, no new adverse events 
were found in comparison with studies that were done previously. The 
most common adverse event was skin irritation from the Novo-TTF 
device being placed directly on the scalp.3 
 
DISCUSSION 
 The current standard protocol for patients with recurrent GBM 
consists of a combination of chemotherapy, radiation, and tumor 
resection surgery. Recently, there have been studies1,3 that have 
proven the NovoTTF-100A system to be an effective treatment for 
overall survival in glioblastoma patients.  
The most current study done by Stupp et al1 was terminated 
prior to completion due to the overwhelming results. The NovoTTF-
100A system was then FDA approved based on the study’s results, and 
patients have continued to benefit from its use. While this treatment 
option has shown to be beneficial, it has not been added to the 
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standard of care for all GBM patients. This systematic review raises the 
question if the NovoTTF-100A system could be an effective addition to 
the standard of care in GBM patients. 
Both the Stupp et al1 and Mrugala et al study3 showed an 
increase in median OS for patients treated with the NovoTTF-100A 
system. The Stupp et al study,1 it showed a 38% reduction in death in 
those patients treated with combination NovoTTF and chemotherapy 
as well as a 3.1-month increase in median progression-free survival. 
The Mrugala et al study3 showed a median OS of 9.6 months in those 
treated with TTF therapy plus chemotherapy compared to the median 
OS found in the prior EF-11 trial of 6.6 months. Data from studies has 
shown that recurrent GBM patients treated with one of the front-line 
chemotherapy medications temozolomide and surgical resection 
typically have median OS of 6-9 months.5  
 In a feasibility study2 that compared TTF alone to the physician’s 
choice of best chemotherapy, quality of life was analyzed using a 
survey given every 3 months throughout treatment. The study found 
that the group that had chemotherapy suffered much higher rates of 
toxicity, adverse events, and a lower quality of life. Those in the TTF 
therapy group demonstrated a higher quality of life in the categories of 
cognitive, emotional, and role functioning. The adverse events 
recorded in the group with TTF therapy alone was similar to the Stupp 
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et al study,1 showing localized skin irritation. The study2 did not show 
a difference in overall survival between the 2 groups, but it did show 
that TTF therapy had similar outcomes to chemotherapy alone. With 
the significant increase in quality of life, decrease in adverse effects 
and systemic toxicity, all with similar outcomes in overall survival it 
shows that the TTF therapy may be a substitute for chemotherapy in 
patients that choose this option. Patients with poor prognosis may 
choose to use a more non-invasive therapy in the time that they have 
to fight the aggressive cancer, and such a choice could be offered by 
the clinician.  
 The NovoTTF-100A system does have a positive impact on 
clinical practice, as it has shown to prolong survival in patients, lead to 
fewer recurrences, reduced adverse effects in comparison to other 
treatments typically used, ease of use, and improved quality of life. It 
is still unclear as to what the ideal patient would be to receive 
NovoTTF-100A System therapy. It seems that TTF therapy works best 
when used as a treatment after first recurrence, on patients with a 
higher KPS scores (>90), and those that have not used bevacizumab 
as a prior treatment.3 Compliance is also vital for treatment success, 
and must be considered with patient selection. The device must be 
worn continuously for >18 hours a day for at least 4 weeks for the 
best outcomes.1,3 There was no difference found in success of 
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treatment in patients that have had prior surgical debulking 
procedures. 
Cost may also be a concern. On average, the NovoTTF-100A 
system costs $21,000 a month.6 The device comes with a treatment 
kit, and those are leased through the manufacturer Novocure. The 
median treatment length for the NovoTTF-100A system is roughly 4.1 
months, which would total to about $86,000.7 Medicare does not cover 
the device, and it was estimated that 1:3 private payers will cover 
some cost of the device.7 The device is acquired by the patient when 
prescribed, so the cost for the healthcare provider is related to the 
staff training time and teaching the patient how to use the device. In 
order for providers to prescribe the device, they must participate in a 
4-hour training that is held by the manufacturer. 
The standard treatment regimen for glioblastoma consists of a 
combination of chemotherapy, radiation therapy, and surgical 
resection. One of the primary chemotherapy agents temozolomide 
(Temodar) can cost from $1,600-$4,600 per month.8 And additional 
necessary treatments can cost up to $9,000 per month.8 These stated 
costs do not include surgical resection(s), which would add a sizable 
amount to the total. 
 There were several limitations to both the Stupp et al1 and 
Mrugala et al3 studies. There is a relatively high risk of bias in both 
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studies, as the company Novocure that manufactured the NovoTTF 
device funded the studies and had members of the company involved 
in the study. Many of the studies available are all advertised on their 
website as well. There was also high variability in the patient 
populations studied, especially due to the non-controlled, observation 
aspect of the Mrugala et al study.3 In addition, there was great 
variability in the patient’s prior treatments which had the potential to 
skew some data. Another limitation is that studies did not differentiate 
if the NovoTFF therapy should be recommended for all patients with 
recurrent GBM, despite prognosis at diagnosis, recurrence number, 
disease severity, and previous treatments. 
 
 While the Novo-TTF-100A system does seem to have the 
potential to be beneficial for all recurrent GBM patients, prognostic 
factors studied need to be more controlled with the addition of 
NovoTTF to have a more accurate representation of what patients will 
benefit the most. While it is not likely a study can be done in 
comparison to a placebo or no treatment group due to ethical 
considerations of the condition, more studies could be done in 
comparison to determine if the NovoTTF therapy alone is more 
beneficial or in combination with chemotherapy. Many of the previous 
studies1,3 have had several compounding variables such as prior 
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surgery, bevacizumab use, recurrence number, first time treatment, 
and KPS score, so it is difficult to determine which of those variables 
may have a favorable or unfavorable outcome in combination with 
NovoTTF. 
 
CONCLUSION 
The NovoTTF-100A System does seem to be an effective 
treatment for patients with recurrent supratentorial glioblastoma. 
Studies completed to this date have demonstrated a variety of patients 
that benefit from the treatment, all with varying prognosis, disease 
states, and prior or concurrent treatment.  The cost of treatment with 
Novo-TFF-100A will vary patient to patient, as does the cost of the 
standard treatment regimen.  It is possible that the cost of Novo-TTF-
100A will be comparable to the standard treatment, which proves that 
cost should not be a limiting factor for providers introducing the Novo-
TTF-100A as a potential treatment option. 
While the therapy has shown to be beneficial, more studies with 
less risk of a bias are needed to distinguish who wouldn’t benefit from 
the therapy, especially in comparison to the current standard protocol 
for treatment of GBM. Although the NovoTTF device needs to continue 
to be reviewed and studied, it has enough evidence that it could be 
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considered by clinicians in treatment of patients with GBM. There are 
limited adverse events associated with the device, patients have 
reported a higher quality of life with the NovoTTF than comparable 
current treatments, and through the studies discussed in this review it 
showed to have a prolonged median OS as well as increased 
progression-free survival.  
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Table 1: Survival Outcome Quality Assessment of Reviewed 
Articles 
Study 
Design Downgrade Criteria 
Upgrade 
Criteria 
Quality 
 
 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
 
 
Stupp et 
al 
RCT Seriousa,b Not Serious Not Serious Not Serious Likelyc None Low 
Mrugala 
et al 
Cohort Not Serious Not Serious Not Serious Not Serious Likelyc None Very 
Low 
 
a Lack of blinding of participants & data collectors 
b Trial stopped early 
c Both studies were funded by the company who made the NovoTTF-100 A System 
 
 
 
Table 2. Summary of Findings – Stupp et al1 
Population Median survival for 
treatment groups in 
months (95% CIs) 
Median survival for 
control group in 
months (95% CIs) 
HR (CIs) 
Progression-free survival 
in the ITT population 
7.1 (5.9-8.2) 4.0 (3.3-5.2) 0.62 (98.7%, 0.43-0.89)  
Overall survival in the 
per-protocol population 
20.5 (16.7-25.0) 15.6 (13.3-19.1) 0.64 (99.4%, 0.42-0.98)  
Overall survival in the 
ITT population 
19.6 (16.6-24.4) 16.6 (13.6-19.2) 0.74 (95%, 0.56-0.98)  
 
 
 
